Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935349 | 0.91 | BACE1 (0.49) | BACE1GPR119KCNH2LMNANR1H2 | |
| SCHEMBL31402917 | 0.90 | RET (0.47) | BACE1GPR119DRD4RET | |
| SCHEMBL31402999 | 0.86 | RET (0.48) | BACE1GPR119DRD4RETEGLN2 | |
| SCHEMBL23220924 | 0.86 | MEN1 (0.49) | GPR119LMNANR1H2NR1H3ALDH1A1 | |
| SCHEMBL31403108 | 0.85 | CYP11B2 (0.54) | BACE1RET | |
| SCHEMBL652725 | 0.85 | MEN1 (0.52) | GPR119LMNANR1H2NR1H3ALDH1A1 | |
| SCHEMBL29665264 | 0.85 | MAPT (0.54) | BACE1GPR119LMNANR1H2NR1H3 | |
| SCHEMBL594432 | 0.85 | MAPT (0.54) | BACE1GPR119LMNANR1H2NR1H3 | |
| SCHEMBL2459991 | 0.85 | GPR119 (0.50) | GPR119LMNANR1H2NR1H3ALDH1A1 | |
| SCHEMBL2462125 | 0.84 | ALDH1A1 (0.51) | BACE1GPR119LMNANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-10239849-B2 | Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. | 2019-03-26 | — | — | US | disclosed |
| US-20180327374-A1 | Cyanopyridine Derivatives as Liver X Receptor Beta Agonists, Compositions, and Their Use | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013051672-A1 | MEDICINAL AGENT COMPRISING THIAZOLIDINE DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | 株式会社ヤクルト本社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-19 | — | — | US | disclosed |
| WO-2011115183-A1 | NOVEL MONOCYCLIC PYRIMIDINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-09-22 | — | — | WO | disclosed |
| WO-2009079593-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | BACE1 1978/4885GPR119 58/4885DRD4 848/4885 |
| US-20180327374-A1 | Cyanopyridine Derivatives as Liver X Receptor Beta Agonists, Compositions, and Their Use | NR1H2, NR1H3, ADRB1 | BACE1 190/4885GPR119 9/4885DRD4 984/4885 |
| US-10239849-B2 | Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, ADRB1 | BACE1 190/4885GPR119 9/4885DRD4 984/4885 |
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | BACE1 1635/4885GPR119 844/4885DRD4 4052/4885 |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | BMP1, BMPR2, BMP2 | BACE1 118/4885GPR119 629/4885DRD4 4163/4885 |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | BMP1, BMPR2, BMP2 | BACE1 118/4885GPR119 629/4885DRD4 4163/4885 |
| US-10005774-B2 | Syk inhibitors | SYK, BTK, LYN | BACE1 1718/4885GPR119 869/4885DRD4 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.